# EDGAR Filing Document

**Accession Number:** 0001398733
**File Stem:** 0001214659-26-000711
**Filing Date:** 2026-1
**Character Count:** 18181
**Document Hash:** 49ba13f61f97b307fe4104e85ba885c2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-26-000711.hdr.sgml**: 20260121

**ACCESSION NUMBER**: 0001214659-26-000711

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260121

**DATE AS OF CHANGE**: 20260121

**EFFECTIVENESS DATE**: 20260121

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aquestive Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001398733
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 208623253
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292859
- **FILM NUMBER:** 26548520

**BUSINESS ADDRESS:**
- **STREET 1:** 30 TECHNOLOGY DRIVE
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059
- **BUSINESS PHONE:** 908-941-1900

**MAIL ADDRESS:**
- **STREET 1:** 30 TECHNOLOGY DRIVE
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MonoSol Rx, Inc.
- **DATE OF NAME CHANGE:** 20070507

As filed with the Securities and Exchange Commission on January 21, 2026

Registration No. 333-_______

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**Aquestive Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **30 Technology Drive**<br> **Warren, NJ 07059** | **82-3827296** |
| (State or Other Jurisdiction of<br> Incorporation or Organization) | (Address of Principal Executive<br> Offices)<br> (Zip Code) | **(**I.R.S. Employer Identification No.) |

---

**Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended**

(Full title of the plan)

**A. Ernest Toth, Jr.**

**Chief Financial Officer**

**Aquestive Therapeutics, Inc.**

**30 Technology Drive**

**Warren, NJ 07059**

(Name and address of agent for service)

**(908) 941-1900**

(Telephone number, including area code, of agent for service)

*Copies of all communications to**:***

**Lori J. Braender**

**Chief Legal Officer, Chief Compliance Officer and Corporate Secretary**

**Aquestive Therapeutics, Inc.**

**30 Technology Drive**

**Warren, NJ 07059**

**908-941-1900**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer □ Accelerated filer □ <br> Non-accelerated filer 🗷 Smaller reporting company 🗷 <br> Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. □

**EXPLANATORY NOTE**

This Registration Statement is being filed by Aquestive Therapeutics, Inc. (the "Registrant") for the purpose of registering an additional 4,881,772 shares of common stock, par value $0.001 per share (the "Common Stock"), of the Registrant available for issuance under the Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended (the "2018 Plan"), pursuant to provisions of the 2018 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan. The Registrant previously filed with the Securities and Exchange Commission (the "Commission") registration statements on Form S-8 on July 27, 2018 (File No. 333-226399), January 8, 2021 (File No. 333-251984), January 7, 2022 (File No. 333-262051), January 18, 2023 (File No. 333-269292), August 9, 2023 (File No. 333-273857), February 12, 2024 (File No. 333-277015), and January 24, 2025 (File No. 333-284490) (collectively, the "Prior Registration Statements") registering shares of Common Stock issuable under the 2018 Plan. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by this Registration Statement below.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents, as originally filed with the Commission by the Registrant, are incorporated herein by reference; provided, however, that any reports or portions thereof that are furnished, including under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items, shall not be deemed incorporated by reference in this Registration Statement:

(a) The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with
the Commission on March 5, 2025;

(b) The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with
the Commission on May 12, 2025;

(c) The Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the
Commission on August 11, 2025;

(d) The Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with
the Commission on November 5, 2025;

(e) The Registrant's Current Reports on Form 8-K, filed with the Commission on February 12, 2025, June
11, 2025, July 15, 2025, August 14, 2025, August 15, 2025, October 8, 2025 and January 9, 2026; and

(f) The description of the Common Stock contained in the Registrant's Registration Statement on Form
8-A (File No. 001-38599) filed with the Commission on July 20, 2018, pursuant to Section 12(b) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act"), as updated by the description of the Common Stock contained in Exhibit 4.7 to the Registrant's
Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on March 11, 2020, including any amendment
or report filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by reference from the date of filing of such documents; provided, however, that any reports or portions thereof that are furnished, including under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items, shall not be deemed incorporated by reference in this Registration Statement. Any statement contained herein or in a document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for all purposes to the extent that a statement contained in this Registration Statement or in any other subsequently filed document which is incorporated by reference herein modifies or replaces such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **<u>Exhibit Number</u>** | **<u>Description of Exhibit</u>** |
| **4.1** | **[Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended (filed as Exhibit 4.1 to the Registration Statement on Form S-8 of the Registrant (File No. 333-273857), as filed on August 9, 2023 and incorporated by reference herein).](https://www.sec.gov/Archives/edgar/data/1398733/000121465923010930/ex4_1.htm)** |
| **5.1** | **[Legal Opinion of Lori J. Braender, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary, filed herewith.](ex5_1.htm)** |
| **23.1** | **[Consent of KPMG LLP, filed herewith.](ex23_1.htm)** |
| **24.1** | **[Powers of Attorney, filed herewith (included on the signature page of this Registration Statement under the caption "Power of Attorney").](#poa)** |
| **107** | **[Filing Fee Table, filed herewith.](ex-filingfees.htm)** |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Somerset, State of New Jersey, on this 21<sup>st</sup> day of January, 2026.

---

| | |
|:---|:---|
| AQUESTIVE THERAPEUTICS, INC. | AQUESTIVE THERAPEUTICS, INC. |
| By: | /s/ Daniel R. Barber |
| Name: | Daniel R. Barber |
| Title: | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW TO ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel R. Barber, A. Ernest Toth, Jr. and Lori J. Braender, and each or any one of them, as such person's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto, with the Commission, granting unto such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary in connection with such matters and hereby ratifying and confirming all that each such attorney-in-fact, or his agent or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Daniel R. Barber |  | January 21, 2026 |
| Daniel R. Barber | President, Chief Executive Officer and Member of the Board of Directors<br> (Principal Executive Officer) |  |
| /s/ A. Ernest Toth, Jr. |  | January 21, 2026 |
| A. Ernest Toth, Jr. | Senior Vice President, Chief Financial Officer<br> (Principal Financial Officer and Principal Accounting Officer)<br>|  |
| /s/ Gregory B. Brown, M.D. |  | January 21, 2026 |
| Gregory B. Brown, M.D. | Chairman of the Board of Directors |  |
| /s/ John S. Cochran |  | January 21, 2026 |
| John S. Cochran | Member of the Board of Directors |  |
| /s/ Abigail L. Jenkins |  | January 21, 2026 |
| Abigail L. Jenkins | Member of the Board of Directors |  |
| /s/ Julie Krop, M.D. |  | January 21, 2026 |
| Julie Krop, M.D. | Member of the Board of Directors |  |
| /s/ Timothy E. Morris |  | January 21, 2026 |
| Timothy E. Morris | Member of the Board of Directors |  |
| /s/ Marco Taglietti, M.D. |  | January 21, 2026 |
| Marco Taglietti, M.D. | Member of the Board of Directors |  |

---

## Exhibit 5.1

**Exhibit 5.1**

January 21, 2026

Aquestive Therapeutics, Inc.

30 Technology Drive

Warren, NJ 07059

Re: <u>Aquestive Therapeutics, Inc. – Registration Statement on Form S-8</u>

This opinion is submitted in connection with the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") filed by Aquestive Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), relating to the registration under the Securities Act of 1933, as amended (the "<u>Act</u>"), of 4,881,772 shares of common stock of the Company, par value $0.001 per share (the "<u>Shares</u>"), issuable under the Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended (the "<u>Plan</u>").

I am the Chief Legal Officer and Corporate Secretary of the Company and, in that capacity, I, or lawyers employed by the Company acting under my supervision, have examined the written documents constituting the Plan and such other documents and corporate records as I, or they, have deemed necessary or appropriate in order to express the opinions hereinafter set forth.

In my examination of such documents and records, I have assumed the genuineness of all signatures, the authenticity of all documents submitted to me as originals, the legal capacity of natural persons, the conformity with the originals of all documents submitted to me as copies and the authenticity of the originals of such latter documents.

Based upon the foregoing and in reliance thereon, and subject to the assumptions, qualifications, limitations and exceptions set forth herein, I am of the opinion that, when the Registration Statement shall have become effective under the Act and the Shares have been duly issued and delivered in the manner contemplated by the Registration Statement and the Plan, the Shares will be validly issued, fully paid and non-assessable.

The foregoing opinion is limited to the General Corporation Law of the State of Delaware. I express no opinion as to the effect of the laws of any other jurisdiction. The opinion set forth herein is made as of the date hereof and is subject to, and may be limited by, future changes in the factual matters set forth herein, and I undertake no duty to advise you of the same. The opinion expressed herein is based upon the law in effect (and published or otherwise generally available) on the date hereof, and I assume no obligation to revise or supplement such opinion should such law be changed by legislative action, judicial action or otherwise. This opinion letter is provided for use solely in connection with the transactions contemplated by the Registration Statement and may not be used, circulated, quoted or otherwise relied upon for any other purpose without my express prior written consent.

I hereby consent to the use of this opinion letter as an exhibit to the Registration Statement. In giving such consent, I do not hereby concede that I am within the category of persons whose consent is required under Section 7 of the Act, or the Rules and Regulations of the Securities and Exchange Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Lori J. Braender |
| Lori J. Braender |
| Chief Legal Officer and Corporate Secretary |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated March 5, 2025, with respect to the financial statements of Aquestive Therapeutics, Inc. incorporated herein by reference.

/s/ KPMG LLP

Short Hills, New Jersey

January 21, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**Aquestive Therapeutics, Inc.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, par value $0.001 per share | (1) | 457(a) | 4881772 | $3.38 | $16500389.36 | 0.0001381 | $2278.71 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $16500389.36 |  | 2278.71 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $2278.71 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of common stock, par value $0.001 per share (the "Common Stock"), of Aquestive Therapeutics, Inc., a Delaware corporation (the "Registrant"), that become issuable under the Registrant's 2018 Equity Incentive Plan, as amended (the "2018 Plan"), in the event of a stock dividend, stock split, recapitalization or other similar transaction. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and 457(c) of the Securities Act. The proposed maximum offering price per share was calculated on the basis of the average of the high and low prices per share of the Common Stock as reported on the Nasdaq Global Market on January 20, 2026. Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 Plan on January 1, 2026 pursuant to an "evergreen" provision contained in the 2018 Plan. Pursuant to such provision, on January 1st of each year prior to the termination of the 2018 Plan, the number of shares authorized for issuance under the 2018 Plan will be increased by (i) 4.0% of the number of shares of Common Stock outstanding on December 31st of the immediately preceding calendar year or (ii) such lesser amount determined by the Board of Directors of the Registrant in its discretion (the "2018 Plan Evergreen Provision"). Pursuant to the 2018 Plan Evergreen Provision, the number of shares of Common Stock available for issuance under the 2018 Plan was increased by 4,881,772 shares effective January 1, 2026, which is 4.0% of the total number of shares of Common Stock outstanding as of December 31, 2025. This Registration Statement registers these 4,881,772 additional shares of Common Stock for issuance under the 2018 Plan.